Ablink Biotech

Founded in 2016 and based in Chengdu, China, Ablink Biotech operates in the biotechnology sector, focusing on drug development services. In October 2025, Ablink Biotech closed a Series A funding. The company specializes in large molecule drug transfer and optimization services, primarily through its innovative ABLINK® BioAI platform. This platform integrates artificial intelligence with biological drug development, enabling high-throughput screening of therapeutic antibodies from a diverse library of over 300 billion real drug candidates.

The company offers services that include the construction of biological drug libraries, lead optimization, and the development of advanced antibody technologies, all aimed at enhancing drug efficacy and safety. Their client base includes leading pharmaceutical companies and biotechnology firms in both domestic and international markets. Ablink Biotech generates revenue through the provision of specialized drug development services and technology partnerships. The company operates on a B2B model, primarily engaging with pharmaceutical enterprises and biotech companies that require assistance in drug discovery and optimization.

The firm has completed 300 commercial projects, with several entering clinical stages, indicating a robust pipeline of ongoing collaborations that contribute to its revenue stability. The company will utilize series A funding to accelerate innovative development of macromolecule drugs. It plans to expand its offerings and enhance its ABLINK® BioAI platform, while also targeting growth in North America and Europe, where it aims to establish deeper partnerships by the end of 2026.